Antiangiogenic therapies in glioblastoma multiforme

Expert Review of Anticancer Therapy

Volumn 12, Issue 5, 2012, Pages 643-654

  McNamara, Mairéad G ^a   Mason, Warren P ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

angiogenesis; antiangiogenic therapy escape; glioblastoma multiforme; imaging; integrin inhibitors; toxicity; tyrosine kinase inhibitors; VEGF inhibitors; vessel co option

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRIVANIB; BRIVANIB ALANINATE; CABOZANTINIB; CARBOPLATIN; CEDIRANIB; CILENGITIDE; DASATINIB; ENZASTAURIN; ERLOTINIB; IMATINIB; IRINOTECAN; LOMUSTINE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; NVP AEW 541; PAZOPANIB; PEGDINETANIB; RETINOIC ACID; RILOTUMUMAB; SORAFENIB; SUNITINIB; TANDUTINIB; TEMOZOLOMIDE; THALIDOMIDE; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VATALANIB;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BLEEDING; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMBINATION CHEMOTHERAPY; DEATH; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ENDOCRINE DISEASE; FATIGUE; FEMUR HEAD NECROSIS; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMMUNOMODULATION; INTESTINE PERFORATION; KIDNEY FAILURE; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE ATROPHY; MYOPATHY; NAUSEA; NONHUMAN; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEINURIA; RECURRENT CANCER; REVIEW; SALVAGE THERAPY; SIDE EFFECT; STEREOTACTIC BODY RADIATION THERAPY; STOMACH PERFORATION; THROMBOSIS; TUMOR BLEEDING; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VOMITING; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; BRAIN; BRAIN NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84861316819     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.35     Document Type: Review

References (90)

1. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005).
2. Holash J, Maisonpierre PC, Compton D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284(5422), 1994-1998 (1999).
3. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011-1027 (2005).
4. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD 2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1), 83-95 (2007).
5. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 175(3), 409-416 (1972).
6. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumors. Nat. Rev. Neurosci. 8(8), 610-622 (2007).
7. Keunen O, Johansson M, Oudin A et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl Acad. Sci. USA 108(9), 3749-3754 (2011).
8. Hattingen E, Jurcoane A, Bahr O et al. Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neuro Oncol. 13(12), 1349-1363 (2011).
9. Presta LG, Chen H, O'Connor SJ et al. Humanisation of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57(20), 4593-4599 (1997).
10. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009).
11. Moen MD. Bevacizumab: in previously treated glioblastoma. Drugs 70(2), 181-189 (2010).
12. Reardon DA, Desjardins A, Peters KB et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J. Neurooncol. 107(1), 155-164 (2012).
13. Sathornsumetee S, Desjardins A, Vredenburgh JJ et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 12(12), 1300-1310 (2010).
14. Lai A, Tran A, NGHiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 29(2), 142-148 (2011).
15. Chinot OL, de La Motte Rouge T, Moore N et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv. Ther. 28(4), 334-340 (2011).
16. Gutin PH, Iwamoto FM, Beal K. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 75(1), 156-163 (2009).
17. Scott BJ, Quant EC, McNamara MB, Ryq PA, Batchelor TT, Wen PY. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neurooncol. 12(6), 603-607 (2010).
18. Gomez-Manzano C, Holash J, Fueyo J et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro. Oncol. 10(6), 940-945 (2008).
19. deGroot JF, Lamborn KR, Chang SM et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J. Clin. Oncol. 29(19), 2689-2695 (2011).
20. Wachsberger PR, Burd R, Cardi C et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 67(5), 1526-1537 (2007).
21. Yoshiji H, Kuriyama S, Ways DK et al. Protein kinase c lies on the signalling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. 59(17), 4413-4418 (1999).
22. Stambolic V, Suzuki A, de la Pompa JL et al. Negative regulation of PKB/ Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95(1), 29-39 (1998).
23. Graff JR, McNulty AM, Hanna KR et al. The protein kinase C beta-selective inhibitor, enzastaurin (LY317615.HCL), suppresses signalling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 65(16), 7462-7469 (2005).
24. Fine HA, Kim L, Royce C. Results from Phase II trial of Enzastaurin (LY317615) in patients with recurrent high grade gliomas. J. Clin. Oncol. 23(Suppl.), 115S (2005) (Abstract 1504).
25. Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of Enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 28(7), 1168-1174 (2010).
26. Butowski N, Chang SM, Lamborn KR et al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 13(12), 1331-1338 (2011).
27. Kamoun WS, Ley CD, Farrar CT et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol. 27(15), 2542-2552 (2009).
28. Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28(17), 2817-2823 (2010).
29. Mulholland P, Batchelor TT, Neyns B. A Phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients. Proc. ESMO Ann. Oncol. 21, LBA7 (2010).
30. Iwamoto FM, Lamborn KR, Robins HI et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North AmericanBrain Tumor Consortium Study 06-02). Neuro Oncol. 12(8), 855-861 (2010).
31. Siegelin MD, Raskett CM, Gilbert CA, Ross AH, Altieri DC. Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci. Lett. 478(3), 165-170 (2010).
32. Yang F, Brown C, Buettner R et al. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol. Cancer Ther. 9(4), 953-962 (2010).
33. Hainsworth JD, Ervin T, Friedman E et al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 116(15), 3663-3669 (2010).
34. Reardon DA, Vredenburgh JJ, Coan A et al. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J. Neurooncol. 105(3), 621-627 (2011).
35. Carlomagno F, Vitagliano D, Guida T et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62(24), 7284-7290 (2002).
36. Wibom C, Sandstrom M, Henriksson R, Antti H, Johansson M, Bergenheim AT. Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model. Int. J. Oncol. 37(4), 879-890 (2010).
37. Drappatz J, Norden AD, Wong ET et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 78(1), 85-90 (2010).
38. Wen PY, Prados M, Schiff D et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients with progressive glioblastoma (GB). J. Clin. Oncol. 28(15), 181S (2010) (Abstract 2006).
39. Du J, Bernasconi P, Clauser KR et al. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat. Biotechnol. 27(1), 77-83 (2009).
40. Milano V, Piao Y, LaFortune T, deGroot J. Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol. Cancer Ther. 8(2), 394-406 (2009).
41. Premkumar DR, Jane EP, Pollack IF. Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines. Int. J. Oncol. 37(3), 633-643 (2010).
42. Lu-Emerson C, Norden AD, Drappatz J et al. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. J. Neurooncol. 104(1), 287-291 (2011).
43. Reardon DA, Egorin MJ, Desjardins A et al. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 115(10), 2188-2198 (2009).
44. Gerstner ER, Eichler AF, Plotkin SR et al. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J. Neurooncol. 103(2), 325-332 (2011).
45. Brandes AA, Stupp R, Hau P et al. EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur. J. Cancer 46(2), 348-354 (2010).
46. Tucker GC. Integrins: molecular targets in cancer therapy. Curr. Oncol. Rep. 8(2), 96-103 (2006).
47. Maurer GD, Tritschlet I, Adams B et al. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro. Oncol. 11(6), 747-756 (2009).
48. Mikkelsen T, Brodie C, Finniss S et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int. J. Cancer. 124(11), 2719-2727 (2009).
49. Stupp R, Hegi ME, Neyns B et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(16), 2712-2718 (2010).
50. Nabors LB, Fink K, Reardon DA et al. Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: protocol of a multicenter, randomized, open-label, controlled Phase II study. J. Clin. Oncol. 28(Suppl.), 15S (2010) (Abstract TPS151).
51. Stupp R, Van Den Bent MJ, Erridge SC et al. Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, open-label, controlled Phase III trial (CENTRIC). J. Clin. Oncol. 28 (Suppl.), 15S (2010) (Abstract TPS152).
52. Son MJ, Kim JS, Kim MH. Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. Int. J. Oncol. 28(1), 53-59 (2006).
53. Puduvalli VK, Giglio P, Groves MD et al. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol. 10(2), 216-222 (2008).
54. Fadul CE, Kingman LS, Meyer LP et al. A Phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J. Neurooncol. 90(2), 229-235 (2008).
55. Gilbert MR, Gonzalez J, Hunter K et al. A Phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol. 12(11), 1167-1117 (2010).
56. Drappatz J, Wong ET, Schiff D. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 73(1), 222-227 (2009).
57. Nabors LB, Fiveash JB, Markert JM et al. A Phase I trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch. Neurol. 67(3), 313-319 (2010).
58. Jun HT, Sun J, Rex K et al. AMG 102, a fully human anti-hepatocyte growth factor/ scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin. Cancer Res. 13(22 Pt 1), 6735-6742 (2007).
59. Wen PY, Schiff D, Cloughesy TF et al. A Phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 13(4), 437-446 (2011).
60. Mamluk R, Carvajal IM, Morse BA et al. Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. MAbs 2(2), 199-208 (2010).
61. Bhide RS, Lombardo LJ, Hunt JT et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor ofvascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol. Cancer. Ther. 9(2), 369-378 (2010).
62. Ranza E, Mazzini G, Facoetti A, Nano R. In vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation. J. Neurooncol. 96(3), 349-357 (2010).
63. Dresemann G, Weller M, Rosenthal MA et al. Imatinib in combination with hydoxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J. Neurooncol. 96(3), 393-402 (2010).
64. Dong Y, Jia L, Wang X et al. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signalling in malignant glioma cells. Int. J. Oncol. 38(2), 555-569 (2011).
65. Cheng Y, Paz K. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications. IDrugs 11(1), 46-56 (2008).
66. Lehky TJ, Iwamoto FM, Kreisl TN, Floeter MK, Fine HA. Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome. Neurology 76(3), 236-241 (2011).
67. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 6(8), 465-477 (2009).
68. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. 23(15), 3502-3508 (2005).
69. Zuniga RM, Torcuator R, Jain R et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol. 91(3), 329-336 (2009).
70. Vredenburgh JJ, Desjardins JE, Herndon II et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722-4729 (2007).
71. Van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonalds criteria. J. Clin. Oncol. 27(18), 2905-2908 (2009).
72. Wen P, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuroncology working group. J. Clin. Oncol. 28(11), 1963-1972 (2010).
73. Quant EC, Norden AD, Drappatz, J et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 11(5), 550-555 (2009).
74. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3), 220-231 (2009).
75. Fischer C, Jonckx B, Mazzone M et al. Anti PlGF inhibits growth of VEGF (R)- inhibitor-resistant tumors without affecting healthy vessels. Cell 131(3), 463-475 (2007).
76. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat. Rev. Cancer 8(8), 592-603 (2008).
77. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Investigation. 111(9), 1287-1295 (2003).
78. diTomaso E, Snuderl M, Kamoun WS et al. Glioblastoma recurrence after cediranib therapy in patients: lack of 'rebound' revascularization as mode of escape. Cancer Res. 71(1), 19-28 (2011).
79. Relf M, LeJeunes S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor b-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57(5), 963-969 (1997).
80. Sofuni A, Iijima H, Moriyasu F et al. Differnetial diagnosis of pancreatic tumors using ultrasound contrast imaging. J. Gastroenterol. 40(5), 518-525 (2005).
81. Sessa C, Guibal A, Del Conte G, Ruegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat. Clin. Pract. Oncol. 5(7), 378-391 (2008).
82. Horn L, Dahlberg SE, Sandler AB et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J. Clin. Oncol. 27(35), 6006-6011 (2009).
83. Greenfield JP, Jin DK, Young LM et al. Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery 64(5), 819-826 (2009).
84. Huang D, Ding Y, Zhou M et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70(3), 1063-1071 (2010).
85. Xu L, Duda DG, di Tomaso E et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res. 69(20), 7905-7910 (2009).
86. Saidi A, Hagedorn M, Allain N et al. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int. J. Cancer. 125(5), 1054-1064 (2009).
87. Wang SD, Rath P, Lal B et al. EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase. Oncogene doi:10.1038/onc.2012.16 (2012) (Epub ahead of print).
88. Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 26(28), 4672-4678 (2008).
89. Hansen TF, Christensen RD, Andersen RF, Spindler KL, Johnsson A, Jakobsen A. The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial. Int. J. Colorectal Dis. doi:10.1007/ s00384-011-1382-6 (2011) (Epub ahead of print).
90. Murat A, Migliavacca E, Gorlia T et al. Stem cell-related self renewal signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J. Clin. Oncol. 26(18), 3015-3024 (2008).